← Eichor
Study identifier: NCT07197762 Synced from ClinicalTrials.gov · July 30, 2026
● Recruiting

MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults

Condition: Neisseria Meningitidis  ·  Sponsor: Emory University

PhasePhase 4
Planned participants125
Who can joinAll sexes, 18 Years to 25 Years
Healthy volunteersYes

About this study

The goal of this clinical trial is to determine the immunogenicity of certain vaccines in protecting against meningitis B (MenB) in young adults who have previously received a different MenB vaccine. The main questions it aims to answer are: * How many participants are protected against four key types of MenB bacteria before and after getting the new vaccine? * How strong is the immune response after vaccination, and how many people show a noticeable boost in immune response?

This description comes directly from the study's public registry record.

Talk to the study team

Christina Rostad, MD  ·  404-727-2472  ·  Christina.rostad@emory.edu

Jessica McCaffery, PhD  ·  jessica.mccaffery@emory.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Emory Children's Center-Vaccine Research ClinicAtlanta, Georgia, United StatesRecruiting
Hope ClinicAtlanta, Georgia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07197762